Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

BioResearcher Sep. 8 at 12:37 PM

$CPIX It is funny the people on CAPR msg board only like bullish posts, any bearish posters will be on ignored list :-) Msg board is for entertaining only, it will not affect stock price or FDA decision. Why take it so serious. As long as the msg is not offensive, any bullish or bearish msg are fun to read. That is why I posted my opinion on CAPR board. Just for fun. I hope there are more "bashers" on CPIX board, so I can chat with them :-)

0 · Reply

YoloAlfred Sep. 8 at 11:29 AM

$CPIX Question? How much does CAPR drug cost?😬

1 · Reply

Dogfon Sep. 7 at 2:30 PM

$CPIX I know several people are nervous about Capr approval. Dont be - insurance companies aren't going to allow deramoicel first-line.

1 · Reply

NVDAMillionaire Sep. 5 at 7:27 PM

$CPIX Brilliant piece that captures CPIX's situation perfectly. So if you want to update your understanding of CPIX or get to know CPIX better, this is essential reading. https://beyondspx.com/quote/CPIX/cumberland-pharmaceuticals-specialty-portfolio-and-pipeline-drive-growth-momentum-nasdaq-cpix#analysis

2 · Reply

BioResearcher Sep. 4 at 11:00 PM

$CAPR $CPIX Danon is rare disease is similar to DMD . Heart issue is also number 1 cause of death. This trial here is a pivotal trial for AA pathway. FDA requires 2 heart damage biomarkers: Troponin and NT-proBNP. These 2 biomarkers are FDA approved gold standard for heart damage / heart failure diagnostic. Here is from that trial:

0 · Reply

YoloAlfred Sep. 4 at 10:49 PM

$CPIX

0 · Reply

BioResearcher Sep. 4 at 9:03 PM

$CPIX Well, I am glad Ifetroban target only one thing: DMD Cardiomyopath. nothing else. The data shows it can reduce heart damage/ heart failure biomarkers: NT-proBNP and Troponin. Stay tuned for great news !

0 · Reply

haha1978 Sep. 3 at 5:07 PM

$CPIX new pathway that might benefit CPIX if true.

0 · Reply

YoloAlfred Sep. 3 at 3:00 PM

$ESPR Im telling you guy's..might want to add some $CPIX

2 · Reply

YoloAlfred Sep. 3 at 2:53 PM

$CPIX slapped 689 shares

0 · Reply

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 4 weeks ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 4, 2025, 9:05 AM EDT - 5 weeks ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 5 weeks ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jun 23, 2025, 9:05 AM EDT - 2 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 3 months ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 13, 2025, 4:05 PM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 10, 2025, 4:23 AM EDT - 4 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 4 months ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 6 months ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 7:14 PM EST - 6 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 6 months ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 6 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 7 months ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 7 months ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 7 months ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 9 months ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 9 months ago

FDA APPROVES ACETADOTE® sNDA

Nov 9, 2024, 1:17 PM EST - 10 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 10 months ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 10 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 10 months ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 11 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 11, 2024, 12:47 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 11, 2024, 11:51 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 1 year ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 10:06 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 11, 2023, 8:17 AM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 2 years ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 12, 2023, 4:21 AM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

Aug 1, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

Jun 26, 2023, 9:00 AM EDT - 2 years ago

NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS

May 23, 2023, 9:00 AM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

May 15, 2023, 9:00 AM EDT - 2 years ago

CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS

May 13, 2023, 5:45 PM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2023 Earnings Call Transcript

May 9, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update

May 2, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS

Mar 7, 2023, 10:47 PM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 4:23 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022

Feb 28, 2023, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

BioResearcher Sep. 8 at 12:37 PM

0 · Reply

YoloAlfred Sep. 8 at 11:29 AM

$CPIX Question? How much does CAPR drug cost?😬

1 · Reply

Dogfon Sep. 7 at 2:30 PM

$CPIX I know several people are nervous about Capr approval. Dont be - insurance companies aren't going to allow deramoicel first-line.

1 · Reply

NVDAMillionaire Sep. 5 at 7:27 PM

2 · Reply

BioResearcher Sep. 4 at 11:00 PM

0 · Reply

YoloAlfred Sep. 4 at 10:49 PM

$CPIX

0 · Reply

BioResearcher Sep. 4 at 9:03 PM

0 · Reply

haha1978 Sep. 3 at 5:07 PM

$CPIX new pathway that might benefit CPIX if true.

0 · Reply

YoloAlfred Sep. 3 at 3:00 PM

$ESPR Im telling you guy's..might want to add some $CPIX

2 · Reply

YoloAlfred Sep. 3 at 2:53 PM

$CPIX slapped 689 shares

0 · Reply

haha1978 Sep. 3 at 1:46 PM

$CPIX wide spread 3.44/3.76 indicates the algorithm is trying to slow it down. When it tightens the move will happen. Looking forward to testing 4 by eow.

0 · Reply

BioResearcher Sep. 3 at 12:15 PM

$CPIX Great find! Thanks

0 · Reply

haha1978 Sep. 3 at 11:38 AM

$CPIX if it breaks 3.75 above the 200 dma then i think being above both 50 and 200 dma and macd above 0 and rsi above 50 triggers an Aaroon buy signal on the chart. Thats only 5 cents. Could happen today a test of 4.00. Nice volume yesterday 94k shares vs 20k to 30k.

1 · Reply

haha1978 Sep. 3 at 11:15 AM

$CPIX best part of that analysis was this part. https://beyondspx.com/quote/CPIX/cumberland-pharmaceuticals-specialty-portfolio-and-pipeline-drive-growth-momentum-nasdaq-cpix#analysis

0 · Reply

YoloAlfred Sep. 3 at 10:51 AM

$CPIX and my father in-law and Dentist......I go this November to my father in-laws birthday.....lets hope CPIX makes me look like a stock wizard

0 · Reply

YoloAlfred Sep. 3 at 10:48 AM

$CPIX http://beyondspx.com/quote/CPIX/cumberland-pharmaceuticals-specialty-portfolio-and-pipeline-drive-growth-momentum-nasdaq-cpix#analysis

0 · Reply

BioResearcher Sep. 3 at 12:03 AM

$CPIX @YoloAlfred @haha1978 Well, guys, We are like the 3 musketeers who knows the true value of this hidden gem here :-) I am glad we are in this early. See YOU at $20 before Xmas this year. I believe in Santa...

1 · Reply

YoloAlfred Sep. 2 at 11:35 PM

$CPIX like that $3.69 ...just a penny under your $3.70

0 · Reply

haha1978 Sep. 2 at 10:36 PM

$CPIX tomorrow if we break 3.70s we willtest 4.00. Exciting that the macd curled up.

0 · Reply

BioResearcher Sep. 2 at 10:06 PM

$CPIX The potential of Ifetroban is just mind-blowing. One can only see its potential after spending months of doing deep DD. $100+ is my target price.

0 · Reply

haha1978 Sep. 2 at 5:09 PM

$CPIX keeps having bid support. Looking forward to the end of day to see if 3.70s are tested.

0 · Reply

haha1978 Sep. 2 at 3:03 PM

$CPIX i think there is a gap at 3.54 on hourly. After lunch it will be interesting to see what happens. 3.75 bewak is a good start.

0 · Reply

Market Cap	49.52M
Revenue (ttm)	37.87M
Net Income (ttm)	-6.48M
EPS (ttm)	N/A
PE Ratio	33.27
Forward PE	N/A
Profit Margin	-17.11%
Debt to Equity Ratio	0.19

Volume	23,082
Avg Vol	81,338
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	17%
Beta	-0.37
Analysts	Strong Buy
Price Target	$8.50